This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Embers, M. E.
Right arrow Articles by Christensen, N. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Embers, M. E.
Right arrow Articles by Christensen, N. D.

 Previous Article  |  Next Article 

Journal of Virology, October 2002, p. 9798-9805, Vol. 76, No. 19
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.19.9798-9805.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein

Monica E. Embers,1 Lynn R. Budgeon,2 Martin Pickel,2 and Neil D. Christensen1,2*

Department of Microbiology and Immunology,1 Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania2

Received 28 March 2002/ Accepted 26 June 2002

The papillomavirus minor capsid protein, L2, has been shown to exhibit immunogenicity, whereby a variety of B-cell epitopes, predominantly in the amino terminus of L2, have been deduced. However, immunity to L2 in vivo has not been examined extensively. Notably, a common neutralization epitope for human papillomavirus (HPV) types 6 and 16 was mapped to amino acids (aa) 108 to 120. The objectives of this study were to derive antisera from rabbits using the corresponding sequences from rabbit viruses and to assess the ability of these peptides to protect against infection. Synthetic peptides consisting of two overlapping sequences each in the region of aa 94 to 122 of the rabbit oral (ROPV) and cottontail rabbit (CRPV) papillomaviruses were used to immunize rabbits. Rabbits were then infected with both ROPV and CRPV and monitored for the development of oral and cutaneous papillomas, respectively. Serum derived from rabbits immunized with either of the two peptides was shown to (i) react to purified L2 from the cognate virus, (ii) specifically recognize L2 within virus-infected cells, and (iii) neutralize virus in vitro. Following viral challenge, cutaneous papilloma growth was completely absent in rabbits immunized with either CRPV peptide. Likewise, ROPV peptide-immunized rabbits were protected from oral papillomatosis. Challenge of CRPV peptide-immune rabbits with the viral genome resulted in efficient papilloma growth, suggesting a neutralizing antibody-mediated mechanism of protection. These results afford in vivo evidence for the immunogenicity provided by a distinct region of L2 and further support previous evidence for the ability of this region to elicit antiviral immunity.

* Corresponding author. Mailing address: The Jake Gittlen Cancer Research Institute, H059, 500 University Dr., Hershey, PA 17033. Phone: (717) 531-6185. Fax: (717) 531-5634. E-mail: ndc1{at}psu.edu.

Journal of Virology, October 2002, p. 9798-9805, Vol. 76, No. 19
0022-538X/02/$04.00+0     DOI: 10.1128/JVI.76.19.9798-9805.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jagu, S., Karanam, B., Gambhira, R., Chivukula, S. V., Chaganti, R. J., Lowy, D. R., Schiller, J. T., Roden, R. B. S. (2009). Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines. JNCI J Natl Cancer Inst 101: 782-792 [Abstract] [Full Text]  
  • Lin, Z., Yemelyanova, A. V., Gambhira, R., Jagu, S., Meyers, C., Kirnbauer, R., Ronnett, B. M., Gravitt, P. E., Roden, R. B.S. (2009). Expression Pattern and Subcellular Localization of Human Papillomavirus Minor Capsid Protein L2. Am. J. Pathol. 174: 136-143 [Abstract] [Full Text]  
  • Alphs, H. H., Gambhira, R., Karanam, B., Roberts, J. N., Jagu, S., Schiller, J. T., Zeng, W., Jackson, D. C., Roden, R. B. S. (2008). Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl. Acad. Sci. USA 105: 5850-5855 [Abstract] [Full Text]  
  • Gambhira, R., Karanam, B., Jagu, S., Roberts, J. N., Buck, C. B., Bossis, I., Alphs, H., Culp, T., Christensen, N. D., Roden, R. B. S. (2007). A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2. J. Virol. 81: 13927-13931 [Abstract] [Full Text]  
  • Gambhira, R., Jagu, S., Karanam, B., Gravitt, P. E., Culp, T. D., Christensen, N. D., Roden, R. B. S. (2007). Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2. J. Virol. 81: 11585-11592 [Abstract] [Full Text]  
  • Xu, Y., Wang, Q., Han, Y., Song, G., Xu, X. (2007). Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol 56: 907-913 [Abstract] [Full Text]  
  • Gambhira, R., Gravitt, P. E., Bossis, I., Stern, P. L., Viscidi, R. P., Roden, R. B.S. (2006). Vaccination of Healthy Volunteers with Human Papillomavirus Type 16 L2E7E6 Fusion Protein Induces Serum Antibody that Neutralizes across Papillomavirus Species. Cancer Res. 66: 11120-11124 [Abstract] [Full Text]  
  • Hu, J., Peng, X., Schell, T. D., Budgeon, L. R., Cladel, N. M., Christensen, N. D. (2006). An HLA-A2.1-Transgenic Rabbit Model to Study Immunity to Papillomavirus Infection. J. Immunol. 177: 8037-8045 [Abstract] [Full Text]  
  • Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., Kleinschmidt, J. A. (2006). Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1. J. Virol. 80: 2621-2630 [Abstract] [Full Text]  
  • Mahdavi, A., Monk, B. J. (2005). Vaccines Against Human Papillomavirus and Cervical Cancer: Promises and Challenges. The Oncologist 10: 528-538 [Abstract] [Full Text]  
  • Yang, R., Day, P. M., Yutzy, W. H. IV, Lin, K.-Y., Hung, C.-F., Roden, R. B. S. (2003). Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection. J. Virol. 77: 3531-3541 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»